#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Children’s Hospital Boston’s Atopic Dermatitis Center is a program of the Division of Allergy and Immunology, and develops treatments informed by our research. Dr. Lynda Schneider is a principal investigator for the NIH Atopic Dermatitis Research Network (ADRN) which is focused on atopic dermatitis (AD) and its association with both immune and skin barrier defects. Dr. Schneider is also an investigator for a long term study of children who have used topical tacrolimus ointment. Children’s is home to the world’s most extensive research enterprise at a pediatric hospital.
Children’s is researching genetic and environmental risk factors which predispose children to developing atopic dermatitis in an interdisciplinary research project. Our Division of Allergy and Immunology and the Program in Genomics are teaming up to uncover how the disease is caused, find participants who have observable signs of atopic dermatitis and identify possible genetic mutations. Ultimately, the data collected from their study will allow researchers to pursue other hypotheses, and to look for gene-environment interactions in the development of atopic dermatitis.
Children’s Hospital Boston is the first to combine an allergy drug with regular milk drinking to help desensitize a child’s immune system to milk, and thus reduce the allergic reaction to milk. More specifically, the allergy drug omilzumab (marketed by Genentech under the name Xolair®) was paired with gradual increased oral consumption (drinking) of milk to help reduce the overreaction of immunoglobulin E (IgE) to the milk, and thus reduce the allergic reaction.
Nine of the eleven child participants successfully completed the study, and are currently consuming 8 to 12 ounces of milk a day to maintain their tolerance. Learn more, and join the conversation on Children’s Vector blog.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”